Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | BUB1 | O43683 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14425277 | 0.79 | MAPK1 (0.40) | MAPK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL5317544 | 0.77 | NOTUM (0.41) | MAPK1NOTUM | |
| SCHEMBL4863074 | 0.77 | MAPK1 (0.39) | MAPK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL14196714 | 0.77 | MAPK1 (0.39) | MAPK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL4856100 | 0.76 | MAPK1 (0.38) | MAPK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL4860414 | 0.75 | MAPK1 (0.38) | MAPK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL14196720 | 0.75 | MAPK1 (0.38) | MAPK1CCNB2CDK1CCNB1GSK3B | |
| SCHEMBL30667212 | 0.72 | NOTUM (0.64) | MAPK1PDK4NOTUMBUB1BCHE | |
| SCHEMBL7004709 | 0.72 | NOTUM (0.64) | MAPK1PDK4NOTUMBUB1BCHE | |
| SCHEMBL29813840 | 0.71 | MAPK1 (0.54) | MAPK1PDK4NOTUMGPR119NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365071-B2 | Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
| US-7365071-B2 | Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
| US-7365071-B2 | Heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as β-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2008-04-29 | — | — | US | disclosed |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | MUSICKI BRANISLAV | 2007-08-16 | — | — | US | disclosed |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | MUSICKI BRANISLAV | 2007-08-16 | — | — | US | disclosed |
| US-20040097490-A1 | Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials | AVENTIS PHARMA S.A. (FR) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097490-A1 | Novel heterocyclic compounds, preparation process and intermediates, and use as medicaments, in particular as B-lactamase inhibitors and antibacterials | GAA, BBOX1, BPGM | MAPK1 1623/4885CCNB2 1236/4885CDK1 976/4885 |
| US-20070191312-A1 | NOVEL HETEROCYCLIC COMPOUNDS, PREPARATION PROCESS AND INTERMEDIATES, AND USE AS MEDICAMENTS, IN PARTICULAR AS BETA-LACTAMASE INHIBITORS AND ANTIBACTERIALS | GAA, PEPD, MGAM | MAPK1 2427/4885CCNB2 1841/4885CDK1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.